Newspatrolling.com News cum Content Syndication Portal Online
Upgrades Outlook to Top End of the Range Across Parameters
Q3FY2025 Performance Highlights
- Revenue at ₹11,537m, grew 14.6% YoY
- Gross margin at ₹6,735m, grew 25.1% YoY
- EBITDA grew 46.9% YoY to ₹2,103m with EBITDA margin at 18.2%, grew 401bps YoY
- US revenue at $73m, grew 13.7% YoY
- Q3FY25 Reported PAT at ₹900m
- Reported EPS at ₹9.56
Bangalore, India, January 30, 2025 – Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q3FY25) ended December 31, 2024.
Financial Highlights (In ₹ m)
| Particulars | Q3FY25 | Q3FY24 | YoY | Q2FY25 | QoQ | 9MFY25 | 9MFY24 | YoY |
| Revenue | 11,537 | 10,070 | 14.6% | 11,669 | -1.1% | 33,749 | 28,767 | 17.3% |
| Gross Margin | 6,735 | 5,382 | 25.1% | 6,159 | 9.4% | 18,939 | 15,600 | 21.4% |
| Gross Margin % | 58.4% | 53.5% | 493bps | 52.8% | 560bps | 56.1% | 54.2% | 189bps |
| EBITDA | 2,103 | 1,432 | 46.9% | 1,846 | 13.9% | 5,849 | 4,082 | 43.3% |
| EBITDA % | 18.2% | 14.2% | 401bps | 15.8% | 241bps | 17.3% | 14.2% | 314bps |
| Reported PAT | 900 | -68 | 723 | 3,238 | -1,601 | |||
| Operational PAT* | 925 | 33 | 761 | 2,317 | 209 |
*Operational PAT = Reported PAT excluding exceptional items
Numbers presented have been adjusted to reflect the impact of the demerger
Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, “We are pleased to report strong YTD results showcasing a YoY improvement across all key metrics of growth, profitability and efficiency. Our 9MFY25 revenue increased by 17.3% YoY and EBITDA grew by 43.3% YoY despite the demerger of high margin Softgel business. For 9MFY25, the US business recorded a revenue of $214m, a growth of 21.3% YoY, and is well on track to achieve the FY25 outlook of $275m-$290m, post-demerger. Additionally, we are proud to have debuted with an outstanding ESG rating of 76/100 in the S&P Global’s CSA, 2024. We are placed significantly ahead of our peers in the first year of ESG evaluation, underscoring our unwavering commitment to sustainability and the strength of our processes and governance. Looking ahead, we remain focused on executing our strategies to deliver superior business outcomes and drive long-term value for our stakeholders.”
